Please use this identifier to cite or link to this item:
Title: New pyrimido-indole compound CD-160130 preferentially inhibits the KV11.1B isoform and produces antileukemic effects without cardiotoxicity
Authors: Gasparoli, L.
D'Amico, M.
Masselli, M.
Pillozzi, S.
Caves, Rachel
Khuwaileh, Rawan
Tiedke, W.
Mugridge, K.
Pratesi, A.
Mitcheson, John S.
Basso, G.
Becchetti, A.
Arcangeli, A.
First Published: 19-Nov-2014
Publisher: The American Society for Pharmacology and Experimental Therapeutics
Citation: Molecular Pharmacology, 2015, 87 (2), pp. 183-196
Abstract: KV11.1 (hERG1) channels are often overexpressed in human cancers. In leukemias, KV11.1 regulates pro-survival signals that promote resistance to chemotherapy, raising the possibility that inhibitors of KV11.1 could be therapeutically beneficial. However, because of the role of KV11.1 in cardiac repolarization, blocking these channels may cause cardiac arrhythmias. We show that CD-160130, a novel pyrimido-indole compound, blocks KV11.1 channels with a higher efficacy for the KV11.1 isoform B, in which the IC50 (1.8 μM) was approximately 10-fold lower than observed in KV11.1 isoform A. At this concentration, CD-160130 also had minor effects on Kir2.1, KV 1.3, Kv1.5, and KCa3.1. In vitro, CD-160130 induced leukemia cell apoptosis, and could overcome bone marrow mesenchymal stromal cell (MSC)-induced chemoresistance. This effect was caused by interference with the survival signaling pathways triggered by MSCs. In vivo, CD-160130 produced an antileukemic activity, stronger than that caused by cytarabine. Consistent with its atypical target specificity, CD-160130 did not bind to the main binding site of the arrhythmogenic KV11.1 blockers (the Phe656 pore residue). Importantly, in guinea pigs CD-160130 produced neither alteration of the cardiac action potential shape in dissociated cardiomyocytes nor any lengthening of the QT interval in vivo. Moreover, CD-160130 had no myelotoxicity on human bone marrow-derived cells. Therefore, CD-160130 is a promising first-in-class compound to attempt oncologic therapy without cardiotoxicity, based on targeting KV11.1. Because leukemia and cardiac cells tend to express different ratios of the A and B KV11.1 isoforms, the pharmacological properties of CD-160130 may depend, at least in part, on isoform specificity.
DOI Link: 10.1124/mol.114.094920
eISSN: 1521-0111
Embargo on file until: 1-Jan-10000
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics. All rights reserved.
Description: The file associated with this record is under permanent embargo from publication in accordance with the publisher's archiving policy available on the SHERPA/RoMEO website. The full text may be available in the publisher links provided above.
Appears in Collections:Published Articles, Dept. of Cell Physiology and Pharmacology

Files in This Item:
File Description SizeFormat 
Gasparoli et al_2015_Publisher pdf.pdfPublished (publisher PDF)1.82 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.